Navigation Links
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
Date:5/27/2009

uct, AMT-021, results in normalization of the PBGD protein in an animal model of AIP. In this model, the therapy completely prevented the occurrence of attacks and significantly ameliorated the neuropathy that develops in untreated mice. AMT-021 is intended to provide long-term normalization of the PBGD protein in order to prevent acute porphyric attacks and their complications.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases, especially those that are caused by one faulty gene. Currently, AMT has a product pipeline with nine products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... LEIDEN, The Netherlands, July 6 Three ... Therapeutics and InteRNA,Technologies - have joined public-private partnership TI ... on cancer and,inflammatory diseases, have a total budget of ... The new consortium, formed by Syncom, Synvolux Therapeutics, and,University ...
... , NEW YORK, June 30 Betsy McCaughey of the Committee ... hospital infection rates made available by the NYS Department of Health ... have the lowest infection rates - and steer clear of those ... , Betsy McCaughey, a Ph.D., founded RID in 2004 with a ...
Cached Medicine Technology:New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:9/30/2014)... Keystone Symposia will convene the first conference of ... Global Health Series on "The Modes of Action ... immediately following the conclusion of the Grand Challenges Meeting ... of the Keystone Symposia Global Health Series, supported by ... funded travel awards for 36 investigators from developing countries ...
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... Calif., Sept. 30, 2014 Research by UC Irvine ... functions, shedding light on a vital process that determines ... In the online version of Nature Immunology , ... and other Institute for Immunology colleagues describe a critical ... released into the bloodstream. , A T cell is ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... by Blue Star Nutraceuticals designed to help maximize lean, ... that optimizes the body’s absorption of glucose has caught ... , “The main purpose behind Glycodrive is to ... builds lean muscle,” reports Michaels. “Carbs are essential in ...
(Date:9/30/2014)... 30, 2014 Elevate , the latest ... better in and out of the gym by providing natural ... the attention of Shane Michaels, prompting an investigative review. ... the reason most people simply just don’t have the ability ... focused at work, getting the motivation to finish a project, ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... Authorizations and Reduces DenialsGREENWOOD VILLAGE, Colo., March 25 ... cycle solutions for the healthcare industry, today announced ... and denial prevention product for hospitals. Missing authorizations ... 15 percent of all payer-denied claims, and can ...
... Inc., the largest privately held spinal implant manufacturer ... MicroFuse(TM) ST Granules, a unique resorbable polymer bone ... MicroFuse(TM) technology utilizes proprietary combinations of poly (lactic ... patented microsphere process to deliver up to twelve ...
... 50 raises odds almost 4-fold , , WEDNESDAY, March 25 (HealthDay ... fourfold increased risk of melanoma in women under the age ... York University School of Medicine. , Identification of this variation ... test to identify women at high risk for the deadly ...
... ACell, Inc. and its founder, Alan Spievack, MD, ... Spievack described how his severed finger grew back after ... technology is a naturally occurring bioscaffold derived from porcine ... it is resorbed and replaced with new native tissue ...
... Dr. Ching-Hua Wang, Chair of Biology, Geology and Nursing, ... California State University Channel Islands , was recently awarded ... Medicine (CIRM) as a part of their Bridges to Stem ... to receive funding from the program. , , ...
... "Today was a monumental day on Capitol Hill ... long-term services and supports.We commend the Senate Finance Committee ... in this year,s health care reform. Long-term services and ... America,s health care crisis. The needs are great. The ...
Cached Medicine News:Health News:Recondo Technology Announces Authorization and Denial Prevention Software Service 2Health News:Globus Medical's MicroFuse(TM) Technology Engineered for Optimal Strength and Porosity 2Health News:Gene Test May ID Younger Women at Risk for Melanoma 2Health News:CSUCI Receives $1.7 Million Grant for Stem Cell Research Program 2Health News:CSUCI Receives $1.7 Million Grant for Stem Cell Research Program 3Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 2Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 3
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and negative ... inoculation. With these slides, perform QC and ... enhance their education and training programs by ... interpretation, all on one slide! KWIK-QC slides ...
Microbiology QC Slides come with one or two droplets of an air-dried and methanol-fixed microorganism, or a single smear containing a designated microorganism population....
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: